Fountain Therapeutics, a San Francisco, CA-based biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age, closed a $6m Series A-1 financing, bringing its total Series A funding to $11m.
The round was led by Khosla Ventures, with participation from Nan Fung Life Sciences. Fountain previously closed on a $5m Series A financing with Nan Fung Life Sciences in May 2018.
Led by John Dimos, Ph.D., chief executive officer, Fountain Therapeutics is a biopharmaceutical company building a pipeline of therapeutics to treat age-related diseases by reversing cellular age. Its cell-based AI-driven technology platform, accelerated by the expertise of leaders in aging research and computation, extracts cellular features that provide insights into the aging process of cells.
The company intends to use the funds to expand the senior leadership team and enhance the capabilities of its technology platform and to advance novel therapeutics identified by the platform through preclinical testing in animal models.